Slides
Page 1
Q3 and 9M FY 25-26 Earnings Presentation February 2026
Page 2
Disclaimer 2 Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Akums Drugs and Pharmaceuticals Limited. All information contained in this presentation has been prepared solely by Akums Drugs and Pharmaceuticals Limited. Akums Drugs and Pharmaceuticals Limited does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith.
Page 3
Managing Directors’ Message Dear Investors We are pleased to declare the results for Q3FY26 as well as 9MFY26. Q3 FY26 was a strong quarter for Akums. Our healthy operating performance was characterized by strong execution across multiple key segments. CDMO registered a healthy topline growth of more than 16% driven by strong volumes. The international branded formulation business saw significant improvement led by demand recovery across key markets. The quarter also saw benefits of operating leverage playing out in the CDMO business with improved capacity utilization as well as steady ramp up of newer facilities. While API pricing stayed under pressure, stabilization in select molecules and disciplined cost management has helped mitigate impact on the CDMO margins. We continue to work towards reducing losses in the trade generics and API segment by way of portfolio rationalization and tighter control over overheads. Our European CDMO project is progressing as per our stated plans. We successfully advanced regulatory and execution milestones following the receipt of the EUGMP certification for our oral liquids’ facility and are on track to start supplies in FY 28. Plant 1 also received renewal of EUGMP certification, showcasing our continued commitment towards global quality manufacturing. Supply of finished oral formulations from Plant 1 to Europe had already commenced this fiscal. The Zambia project also remains on track with commercial supplies from the Indian plants expected in H1 of FY27. These developments further showcase our progress towards establishing Akums as a global pharmaceutical company. During Q3 FY26, the API business remained under pressure, with pricing softness persisting across key molecules; however, the pace of decline moderated, and ongoing portfolio rationalization and cost optimization initiatives helped contain losses and improve sequential performance. While we continue to operate in a volatile business environment marked by disruptions, we, as Akums, remain focused on our long-term growth drivers that include innovation, operational efficiency, cost controls and strategic partnerships. We reiterate our commitment to creating long term value for our shareholders. Thank you for your continued trust and support. - Sanjeev Jain & Sandeep Jain 3
Page 4
Incorporated in April 2004 Set up of first plant for oral solid dosage form in Haridwar. Established dedicated manufacturing site for Oral Liquid Dosage & Sterile products. Established a nutraceutical facility Expanded into Asian markets. Established R&D lab in Mumbai to venture into regulated market. Received US-NSF Certification for Maxcure Nutravedicsfacility Dedicated facilities for Hormones, Cosmetics and Dermatology. Launched Akumentisto venture into branded formulations. Started dedicated plant for β-lactam anti- infectives and steroids Acquired Parabolic Drugs to venture intoAPI Plant 1 ,2 & 3 received EU- GMP accreditation Listed on NSE and BSE Started new injectable facility ANVISA certified for Plant 3 Two Decades’ Legacy of Expertise, Experience & Trust 2004 2010 2021Build Strengthen Accelerate 2025 4
Page 5
Location 5 Technologically Advanced Manufacturing Capabilities Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Kotdwar Baddi Haridwar Year 2004 2007 2007 2010 2010 2010 2014 2014 2021 2023 2024 Annual Capacity (Cr units) 649 15 39 244 6 252 2.603 732 17 368 36 Capability General General General Hormonal Cosmetics Ayurvedic / Nutraceuticals General β-lactams and steroids Penem anti-infective General General Dosage Forms 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 32 4Oral Solid Oral Liquid Injectable / Sterile External / Topical Key Accreditations* *Received by some or all facilities;
Page 6
R&D Focus Innovative In-house Technologies Inlay Tablet Multiple Tablets in Capsule Smart Tablets Gummies Mouth Melting Powders in Sachet Tri Layered Tablet Tablet In Tablet Bi-layered, Sustained Release Tablet in Tablet 6(1) As of 31st March 2025 Lyophilized Vials Pre-filled syringes Illustrative
Page 7
Key drivers as well as their trends during Q3FY26 Key drivers and their impact on Akums’ performance Strong volume growth, despite muted volumes in the IPM API prices continue to remain soft though initial signs of stabilization Operating leverage and ramp up of new facilities Strong performance in branded exports Akums’ witnessed double digit volume growth even though IPM volumes grew at 1.2%* API prices continued their downward trajectory though some stability witnessed for some molecules. Overall capacity utilization improved to 47% driven by strong volume growth. New facilities ramping up steadily. Exports more than doubled QoQ with healthy growth across focus countries 8* Source: Awacs
Page 8
Financial Performance Highlights Q3 FY 26 8
Page 9
Q3FY26 Performance Highlights 9 Business Vertical Share in Q3 FY26 revenue CDMO 79.0% Domestic Branded Formulation 9.9% API 4.7% International Branded Formulation 4.3% Trade Generics 2.1% Segment Break-upConsolidated Performance* 1,050 cr Total Income (+0.3% YoY) 121 cr 11.6% Adj. EBITDA (-130 bps YoY) 54 cr 5.1% Adj. PAT (-57 bps YoY) 1,194 cr Total Income (+16.5% YoY) 181 cr 15.2% EBITDA (+33.3% YoY) *Including other Income; #Excluding the one time impact of New Labour codes Operating Performance# 1,160 cr Revenue (+14.8% YoY) 147 cr 12.7% EBITDA (+21.0% YoY) 86 cr 7.2% PAT (+29.5% YoY) 68 cr 5.7% PAT (+2.1% YoY) 9
Page 10
9MFY26 Performance Highlights 10 Business Vertical Share in 9M FY26 revenue CDMO 79.1% Domestic Branded Formulation 10.8% API 4.5% International Branded Formulation 3.4% Trade Generics 2.3% Segment Break-upConsolidated Performance* 1,050 cr Total Income (+0.3% YoY) 121 cr 11.6% Adj. EBITDA (-130 bps YoY) 54 cr 5.1% Adj. PAT (-57 bps YoY) 3,295 cr Total Income (+6.4% YoY) 464 cr 14.1% Adj. EBITDA (+15.6% YoY) (Adjusted EBITDA = PBT + fair value changes to financial instrument + finance cost + depreciation and amortization – other income ; Adjusted PAT = PAT + Fair value changes to financial instrument; * Including other income; #Excluding one time impact of New Labour codes) Operating Performance# 3,201 cr Revenue (+4.5% YoY) 370 cr 11.6% Adj EBITDA (+1.0% YoY) 193 cr 5.9% Adj PAT (+1.6% YoY) 175 cr 5.3% Adj PAT (-8.0% YoY) 10
Page 11
Profit and Loss Statement 11 Particulars (Rs Cr) Q3 FY26 Q3 FY25 Y-O-Y (%) Q2 FY26 Q-O-Q (%) 9M FY26 9M FY25 Y-O-Y (%) Revenue 1,160 1,010 14.8% 1,018 14.0% 3,201 3,063 4.5% COGS 679 602 12.6% 593 14.5% 1,853 1,794 3.3% GP Margin % 41.5% 40.4% 41.8% 42.1% 41.4% Employee Expenses 189 176 7.8% 189 0.1% 555 532 4.3% Other Expenses 145 111 30.4% 141 2.5% 423 370 14.4% Adj EBITDA1 147 121 21.0% 94 55.4% 370 367 1.0% Adj EBITDA Margin % 12.7% 12.0% 9.3% 11.6% 12.0% Finance Cost 24 5 362% 23 1.9% 70 30 133% Depreciation & Amort. 40 45 (10.9)% 38 4.7% 114 113 0.9% Exceptional Expenses 18 (5) - - - 18 (8) - Other Income 34 15 136% 32 6.1% 93 35 170% Adj Profit Before Tax 100 91 9.3% 66 51.6% 261 266 (2.0)% Tax 32 25 28.9% 23 38.8% 86 76 13.0% Adj PAT2 68 66 2.1% 43 58.5% 175 190 (8.0)% Adj PAT Margin % 5.7% 6.5% 4.1% 5.3% 6.1% (1 -Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortization – other income ; 2- Adjusted PAT = PAT + Fair value changes to financial instrument) 11
Page 12
Quarterly Performance Trends Revenue (INR Cr.) Adjusted EBITDA1 (INR Cr) 12.6%8.9% Margin % 9.3% 12.7%12.0% Adjusted PAT2# (INR Cr) 6.2%4.1% Margin % 4.1% 7.2%6.5% 12 29.5 %21.0% (1 -Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortization – other income ; 2- Adjusted PAT = PAT + Fair value changes to financial instrument - deferred tax created on brought forward losses (INR 106 cr) in Q4 FY 25; #Excluding one time impact of New Labour codes) 121 94 129 94 147 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 14.8% 1,010 1,056 1,024 1,018 1,160 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 66 44 65 43 86 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26
Page 13
9M Performance Trends Revenue (INR Cr.) Adjusted EBITDA1 (INR Cr) Margin % 11.6%12.0% Adjusted PAT2# (INR Cr) Margin % 5.9%6.1% 13 4.5% 1.0% 1.6% 367 370 9M FY25 9M FY26 3,063 3,201 9M FY25 9M FY26 (1 -Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortization – other income ; 2- Adjusted PAT = PAT + Fair value changes to financial instrument - deferred tax created on brought forward losses (INR 106 cr) in H2 FY 25; #Excluding one time impact of New Labour codes) 190 193 9M FY25 9M FY26
Page 14
Revenue and Margin Deep-Dive – Quarterly 14 Revenue (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortizati on – Other income • Operating leverage led improvement in gross margins and employee expenses • Other expenses increased due to higher power and fuel as well as professional expenses • Strong double digit volume growth • Erosion in API prices responsible for negative price variance • Revenue growth driven by CDMO and International formulations • In line with outlined strategy, consolidation of trade generics continues
Page 15
Revenue and Margin Deep-Dive – 9M 15 Revenue (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortizati on – other income • Operating leverage led improvement in gross margins • Other expenses increased due to higher power and fuel expenses • Volumes grew despite muted volumes in the IPM • Erosion in API prices responsible for negative price variance • 9M revenue growth driven by improved volumes in CDMO • Erosion in API prices and consolidation in trade generics responsible for degrowth across these segments
Page 16
16 Segmental Quarterly Performance CDMO Revenue Domestic Branded Formulation Revenue International Branded Formulation Revenue Trade Generics Revenue API Revenue CDMO EBITDA 10.5%15.4% 13.7% Margin % Trade Generics EBITDA API EBITDA Domestic Branded Formulation EBITDA 18.5% 21.6% 22.2% International Branded Formulation EBITDA 18.3% 24.5% 25.8% 787 804 916 Q3 FY25 Q2 FY26 Q3 FY26 110 122 115 Q3 FY25 Q2 FY26 Q3 FY26 42 22 50 Q3 FY25 Q2 FY26 Q3 FY26 121 84 126 Q3 FY25 Q2 FY26 Q3 FY26 30 24 25 Q3 FY25 Q2 FY26 Q3 FY26 20 26 25 Q3 FY25 Q2 FY26 Q3 FY26 40 44 54 Q3 FY25 Q2 FY26 Q3 FY26 8 5 13 Q3 FY25 Q2 FY26 Q3 FY26 -8 -3 -3 Q3 FY25 Q2 FY26 Q3 FY26 -11 -14 -7 Q3 FY25 Q2 FY26 Q3 FY26 16.3%YoY13.8%QoQ 4.2%YoY-5.8%QoQ 18.0%YoY123%QoQ -18.0%YoY1.7%QoQ 35.4%YoY22.0%QoQ
Page 17
17 Segmental 9M Performance CDMO Revenue Domestic Branded Formulation Revenue International Branded Formulation Revenue Trade Generics Revenue API Revenue CDMO EBITDA 15.4% 13.0% Margin % Trade Generics EBITDA API EBITDA Domestic Branded Formulation EBITDA International Branded Formulation EBITDA 2,368 2,533 9M FY25 9M FY26 330 344 9M FY25 9M FY26 103 108 9M FY25 9M FY26 365 330 9M FY25 9M FY26 92 72 9M FY25 9M FY26 54 68 9M FY25 9M FY26 169 144 9M FY25 9M FY26 19 26 9M FY25 9M FY26 -18 -12 9M FY25 9M FY26 -37 -28 9M FY25 9M FY26 7.0% 4.3% -21.8% -15.0% 16.5% 19.7% 18.3% 24.6% 4.6%YoY YoY YoY YoY YoY
Page 18
Thank You For further information, contact: 18 Siddharth Rangnekar / Shruti Joshi CDR, India Tel: +91 97699 19966 / 75065 67349 Email: siddharth@cdr-india.com / shruti@cdr-india.com IR Desk Akums Drugs and Pharmaceuticals Ltd Email: investors@akums.net/ankit.jain@akums.net